Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer

Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patient...

B. Lan, Faliang Xu, Tao Sun et al. · 0 citations
Open access Aug 2026

Interpretable machine learning prognostication of gastroenteropancreatic neuroendocrine tumors across Chinese and United States cohorts

Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) display marked clinical heterogeneity, and conventional prognostic indicators such as TNM stage and Ki-67 index provide limited individualized risk discrimination. We aimed to develop and externally validate interpretable machine learning models for sur...

Yang-Wei Fan, Yu-Qian Yang, Ke Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.